Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$8.92−0.40 (-4.29%)
Close on Nov 17, 2026Market cap $147.90MP/E –Yield –
Sutro Biopharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Sutro Biopharma's free cash flow for the twelve months ending Sep 30, 2019 was -$60.03M, down 585.6% year over year. For fiscal 2018 it was $11.13M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $11.13M | – |
| FY2017 | Dec 31, 2017 | -$40.39M | – |
| FY2016 | Dec 31, 2016 | -$17.55M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2020 | Mar 31, 2020 | -$19.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.79M | -135.6% |
| Q2 FY2019 | Jun 30, 2019 | -$16.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.73M | – |
| Q3 FY2018 | Sep 30, 2018 | $47.21M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.98M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.37M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.50M | – |
See a number that looks wrong?